Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 1873-1885

  Meka, Durga Praveen ^a   Müller Rischart, Anne Kathrin ^b   Nidadavolu, Prakash ^a   Mohammadi, Behnam ^a   Motori, Elisa ^c   Ponna, Srinivas Kumar ^a   Aboutalebi, Helia ^a   Bassal, Mahmoud ^a   Annamneedi, Anil ^a   Finckh, Barbara ^a   Miesbauer, Margit ^c   Rotermund, Natalie ^d   Lohr, Christian ^d   Tatzelt, Jörg ^c,e   Winklhofer, Konstanze F ^b,c,e,f   Kramer, Edgar R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Ruhr University Bochum ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARKIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; ADENOSINE TRIPHOSPHATE; GDNF PROTEIN, MOUSE; HYBRID PROTEIN; PROTEIN RET; RET PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE INTERACTION; IMMUNOHISTOCHEMISTRY; INNERVATION; MALE; MITOCHONDRION; MORPHOLOGY; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; WHOLE CELL PATCH CLAMP; ANIMAL; ANXIETY; BIOSYNTHESIS; CELL LINE; DEFICIENCY; DISEASE COURSE; EXPLORATORY BEHAVIOR; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE DEGENERATION; PARKINSONISM; PATHOLOGY; PHYSIOLOGY; ROTAROD TEST; TRANSGENIC MOUSE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANXIETY; CELL LINE; CELL SIZE; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; EXPLORATORY BEHAVIOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOCHONDRIA; NERVE DEGENERATION; NF-KAPPA B; PARKINSONIAN DISORDERS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-RET; RECOMBINANT FUSION PROTEINS; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UBIQUITIN-PROTEIN LIGASES;

EID: 84929018009     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79300     Document Type: Article

References (59)

1. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron. 2010;66(5):646-661.
2. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet. 2011;12:301-325.
3. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007;30(5):244-250.
4. Kramer ER, et al. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 2007;5(3):e39.
5. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gomez-Diaz R, Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci. 2008;11(7):755-761.
6. Aron L, Klein P, Pham TT, Kramer ER, Wurst W, Klein R. Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons. PLoS Biol. 2010;8(4):e1000349.
7. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038-3062.
8. Corti O, Brice A. Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease. Curr Opin Neurobiol. 2013;23(1):100-108.
9. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12(1):9-14.
10. Bian M, et al. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PLoS One. 2012;7(6):e39953.
11. Lo Bianco C, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A. 2004;101(50):17510-17515.
12. Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for α-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther. 2005;16(2):262-270.
13. Fallon L, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol. 2006;8(8):834-842.
14. Fusco D, et al. The RET51/FKBP52 complex and its involvement in Parkinson disease. Hum Mol Genet. 2010;19(14):2804-2816.
15. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-318.
16. Itier JM, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet. 2003;12(18):2277-2291.
17. Kowsky S, et al. RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc Natl Acad Sci U S A. 2007;104(50):20049-20054.
18. Kramer ER, et al. Cooperation between GDNF/Ret and ephrinA/EphA4 signals for motoraxon pathway selection in the limb. Neuron. 2006;50(1):35-47.
19. Parlato R, Rieker C, Turiault M, Tronche F, Schutz G. Survival of DA neurons is independent of CREM upregulation in absence of CREB. Genesis. 2006;44(10):454-464.
20. Turiault M, et al. Analysis of dopamine transporter gene expression pattern - generation of DAT-iCre transgenic mice. FEBS J. 2007;274(14):3568-3577.
21. Goldberg MS, et al. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem. 2003;278(44):43628-43635.
22. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30(5):194-202.
23. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(5):2283-2301.
24. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW. Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem. 2004;91(5):1025-1043.
25. Sagna A, Gallo JJ, Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease. Parkinsonism Relat Disord. 2014;20(7):708-715.
26. Beitz JM. Parkinson's disease: a review. Front Biosci (Schol Ed). 2014;6:65-74.
27. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Bjorklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012;4(163):163ra56.
28. Greenbaum L, et al. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Front Neurosci. 2013;7(52):1-9.
29. Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A. 2008;105(32):11364-11369.
30. Gispert S, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One. 2009;4(6):e5777.
31. Palacino JJ, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem. 2004;279(18):18614-18622.
32. Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, Lubbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet. 2007;16(20):2377-2393.
33. Pilsl A, Winklhofer KF. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. 2012;123(2):173-188.
34. Irrcher I, et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet. 2010;19(19):3734-3746.
35. Klein P, et al. Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants. EMBO J. 2014;33(4):341-355.
36. Deas E, Wood NW, Plun-Favreau H. Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta. 2011;1813(4):623-633.
37. Henn IH, et al. Parkin mediates neuroprotection through activation of IκB kinase/nuclear factor-kappaB signaling. J Neurosci. 2007;27(8):1868-1878.
38. Muller-Rischart AK, et al. The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. Mol Cell. 2013;49(5):908-921.
39. Lutz AK, et al. Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem. 2009; 284(34):22938-22951.
40. Schwarz TL. Mitochondrial trafficking in neurons. Cold Spring Harb Perspect Biol. 2013;5(6):a011304.
41. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem. 2013;288(15):10736-10741.
42. Leknes S, Tracey I. A common neurobiology for pain and pleasure. Nat Rev Neurosci. 2008;9(4):314-320.
43. Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. ASN Neuro. 2010;2(5):e00045.
44. Mills CD, Allchorne AJ, Griffin RS, Woolf CJ, Costigan M. GDNF selectively promotes regeneration of injury-primed sensory neurons in the lesioned spinal cord. Mol Cell Neurosci. 2007;36(2):185-194.
45. Zhang L, et al. GDNF-enhanced axonal regeneration and myelination following spinal cord injury is mediated by primary effects on neurons. Glia. 2009;57(11):1178-1191.
46. Koyano F, et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature. 2014;510(7503):162-166
47. Meissner WG, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011;10(5):377-393.
48. Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013;28(1):96-109.
49. Hayashi H, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene. 2000;19(39):4469-4475.
50. Ohgami N, et al. c-Ret-mediated hearing losses. Int J Clin Exp Pathol. 2012;5(1):23-28.
51. Santoro M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267(5196):381-383.
52. Sawamoto K, et al. Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. Proc Natl Acad Sci U S A. 2001;98(11):6423-6428.
53. Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U, Tatzelt J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J Biol Chem. 2003;278(47):47199-47208.
54. Yang L, Beal MF. Determination of neurotransmitter levels in models of Parkinson's disease by HPLC-ECD. Methods Mol Biol. 2011;793:401-415.
55. Rossel M, et al. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene. 1997;14(3):265-275.
56. Krappmann D, Wulczyn FG, Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-κB inhibitor IκBα in vivo. EMBO J. 1996;15(23):6716-6726.
57. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell. 1997;91(2):243-252.
58. Okita C, Sato M, Schroeder T. Generation of optimized yellow and red fluorescent proteins with distinct subcellular localization. Biotechniques. 2004;36(3):418-424
59. Bouman L, et al. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ. 2011;18(5):769-782.